Video

Dr. El-Khoueiry Discusses Research on Biomarkers in HCC

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses research on biomarkers in hepatocellular carcinoma (HCC).

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses research on biomarkers in hepatocellular carcinoma (HCC).

An important area of research in HCC is on biomarkers, says El-Khoueiry. Given that patients with advanced HCC have access to multiple therapies, it would be beneficial to know which patients are going to respond to which agents. To that end, some preliminary research regarding biomarkers for anti—PD-1 agents have emerged, adds El-Khoueiry.

For example, in the phase I/II CheckMate-040 trial, which evaluated the safety and efficacy of nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) in advanced HCC, investigators showed that PD-L1 expression was associated with a higher objective response rate. However, PD-L1 was not shown to be a definitive biomarker as there were responders in the PD-L1—negative group of the trial as well. Right now, it is an evolving area of research. As such, biomarkers should not be used to select patients for treatments in current practice, concludes El-Khoueiry.

Related Videos
Dr Petrella on Selecting Frontline Therapy in Metastatic Melanoma
Omid Hamid, MD
Marlana M. Orloff, MD
Mark Faries, MD
6368672538112
Dr Jabbour on Bleximenib Monotherapy in KMT2A+ or NPM1+ R/R Acute Leukemia
Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.
Rene Y. McNall-Knapp, MD, pediatric hematologist-oncologist, Jimmy Everest Center, Oklahoma Children’s Hospital OU Health; professor, Department of Pediatrics, University of Oklahoma Health Sciences Center
John Andrew Livingston, MD, MS
Howard Colman, MD, PhD, Jan M. Huntsman Presidential Professor, Department of Neurosurgery, member, Brain Tumor Research Team, and leader, Center for Neurologic Cancers, Huntsman Cancer Institute, University of Utah